US Drug Recall Register
Class I · High risk Terminated Initiated Sep 27, 2011 (15 years ago)

Taztia XT

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Labeling: Label Mix Up; packages labeled as Thiamine actually contain Diltiazem Capsules

What was recalled

Taztia XT (Diltiazem HCl) Capsules, 120 mg, Rx, Packaged and labeled as Thiamine. Re-Packaged By: Shamrock Medical Solutions, Lewis Center, Ohio, Mfg: Watson Laboratories, Corona, CA NDC 62037-0696-90

Recalling firm
Shamrock Medical Solutions Group LLC
NDC code
62037-0696-90
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1446-2014

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Diltiazem recalls

See all
Class II · Moderate risk Ongoing

Diltiazem Hydrochloride Extended-Release Capsules

Reason cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.

Glenmark Pharmaceuticals Inc., USA NDC 16714-555-01 D-0098-2025
Class II · Moderate risk Ongoing

Diltiazem Hydrochloride Extended-Release Capsules

Reason cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.

Glenmark Pharmaceuticals Inc., USA NDC 16714-554-01 D-0097-2025
Class II · Moderate risk Ongoing

Diltiazem Hydrochloride Extended-Release Capsules

Reason cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.

Glenmark Pharmaceuticals Inc., USA NDC 16714-553-01 D-0096-2025
Class II · Moderate risk Ongoing

Diltiazem Hydrochloride Extended-Release Capsules

Reason cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.

Glenmark Pharmaceuticals Inc., USA NDC 68462-562-01 D-0095-2025